Polypeptides of
The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
1. A composition comprising an isolated polypeptide having at least 85% similarity to amino acids 63-714 of SEQ ID NO:4; and
a pharmaceutically acceptable adjuvant.
2. The composition of claim 1 , further comprising:
at least one isolated polypeptide having a molecular weight of 92 kDa to 79 kDa, 73 kDa to 63 kDa, 62 kDa to 58 kDa, or 57 kDa to 47 kDa, wherein the at least one polypeptide is isolatable from a Fusobacterium necrophorum subsp. necrophorum when incubated in media comprising an iron chelator and not isolatable when grown in the media without the iron chelator, and wherein the molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions; and
at least one isolated polypeptide having a molecular weight of 108 kDa to 98 kDa or 79 kDa to 69 kDa, wherein the at least one polypeptide is isolatable from a Fusobacterium necrophorum subsp. necrophorum , when incubated in media comprising an iron chelator, is expressed by the Fusobacterium necrophorum subsp. necrophorum when incubated in media without the iron chelator and expressed at an enhanced level during growth in media comprising an iron chelator, and wherein the molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions.
3. The composition of claim 2 , further comprising a polypeptide having at least 85% similarity to amino acids 63-423 of SEQ ID NO:2.
4. The composition of claim 2 , further comprising a polypeptide having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6.
5. The composition of claim 2 , further comprising a polypeptide having at least 85% similarity to amino acids 63-423 of SEQ ID NO:2 and a protein having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6.
6. The composition of claim 2 , wherein the iron chelator is 2,2-dipyridyl.
7. A composition comprising:
at least one isolated polypeptide having a molecular weight of 131 kDa to 121 kDa, 108 kDa to 98 kDa, 92 kDa to 64 kDa, 53 kDa to 43 kDa, or 33 kDa to 19 kDa, wherein the polypeptide is isolatable from a Fusobacterium necrophorum subsp. necrophorum , when incubated in media comprising a zinc chelator and not isolatable when grown in the media without the zinc chelator, and wherein the molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions; and
at least one isolated polypeptide having a molecular weight of 79 kDa to 69 kDa or 65 kDa to 55 kDa, wherein the at least one polypeptide is isolatable from the Fusobacterium necrophorum subsp. necrophorum , when incubated in media comprising a zinc chelator, is expressed by the Fusobacterium necrophorum subsp. necrophorum , when incubated in media without the zinc chelator and expressed at an enhanced level during growth in media comprising the zinc chelator, and wherein the molecular weight is as determined by 10% SDS-PAGE under reducing and denaturing conditions; and
a pharmaceutically acceptable adjuvant,
wherein one of the at least one isolated polypeptides is the polypeptide of claim 1 .
8. The composition of claim 7 , further comprising a polypeptide having at least 85% similarity to amino acids 63-423 of SEQ ID NO:2.
9. The composition of claim 7 , further comprising a polypeptide having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6.
10. The composition of claim 7 , further comprising a polypeptide having at least 85% similarity to amino acids 63-423 of SEQ ID NO:2 and a protein having at least 85% similarity to amino acids 63-736 of SEQ ID NO:6.
11. The composition of claim 7 , wherein the zinc chelator is N,N,N′,N′-Tetrakis (2-pyridylmethyl)-ethylene diamine (TPEN).
12. A method comprising:
administering to a subject an amount of the composition of claim 1 effective to induce the subject to produce antibody that specifically binds to at least one polypeptide of the composition.
13. A method for treating an infection in a subject, the method comprising:
administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a Fusobacterium spp.
14. A method for treating a symptom in a subject, the method comprising:
administering an effective amount of the composition of claim 1 to a subject having or at risk of having an infection caused by a Fusobacterium spp.
15. A method for decreasing colonization in a subject, the method comprising:
administering an effective amount of the composition of claim 1 to a subject colonized by or at risk of being colonized by a Fusobacterium spp.
16. The method of claim 12 wherein the subject is a mammal.
17. The method of claim 16 wherein the mammal is a human, bovine, or ovine.
18. The method of claim 13 wherein the Fusobacterium spp. is F. necrophorum.
19. The method of claim 12 wherein at least 10 micrograms (μg) and no greater than 2000 μg of polypeptide is administered.
20. The method of claim 13 wherein the infection causes a condition selected from metritis, hepatic abscesses, and foot rot.
21. A kit for detecting antibody that specifically binds a polypeptide, comprising in separate containers:
the isolated polypeptide of claim 1 ; and
a reagent that detects an antibody that specifically binds the polypeptide.
22. A recombinant host cell comprising a recombinant polypeptide having at least 85% similarity to amino acids 63-714 of SEQ ID NO:4 and a pharmaceutically acceptable adjuvant.
23. The recombinant host cell of claim 22 , wherein the host cell is E. coli.